Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02162511 · ClinicalTrials.gov registry record · NA
CD34+ Cell Enriched and T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Mismatched Related Donors or Borderline Organ Function
A NA study of Non Malignant Diseases and Malignant Diseases, sponsored by Rajni Agarwal.
- Completed
- Registry status
- NA
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT02162511 is a NA study of Non Malignant Diseases and Malignant Diseases that has completed, run by Rajni Agarwal. The registered enrollment target is 3 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02162511, a NA study of Non Malignant Diseases and Malignant Diseases, has completed, sponsored by Rajni Agarwal.
- COMPLETED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this protocol is to provide access to the CliniMACS® System to hematopoietic cell transplant (HSCT) patients who do not have a matched related donor. The CliniMACS system is currently approved for use in patients who have AML, and a genetically matched sibling donor. Through this protocol, the investigators will be able to offer potentially life-saving transplants to patients who have genetically mis-matched donor, who have no other options for treatment.
Conditions Studied
Interventions
- DEVICE CliniMACS CD34+ cell enrichment and T-cell depletion
Study Locations (1)
California
- Stanford Children's Hospital - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-05 |
| Est. Completion | 2023-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02162511
The ClinicalTrials.gov registry entry for NCT02162511 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rajni Agarwal, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non Malignant Diseases appearing as the primary indexed condition, and to 1 intervention - of which CliniMACS CD34+ cell enrichment and T-cell depletion is the first listed.
NCT02162511 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02162511 about?
NCT02162511 is a clinical study titled "CD34+ Cell Enriched and T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Mismatched Related Donors or Borderline Organ Function". The purpose of this protocol is to provide access to the CliniMACS® System to hematopoietic cell transplant (HSCT) patients who do not have a matched related donor. The CliniMACS system is currently approved for use in patients who have AML, and a genetically matched sibling donor. Through this prot...
What is the current status of trial NCT02162511?
This trial is currently completed. It is a NA study. The enrollment target is 3 participants. The study started on 2014-05. Estimated completion is 2023-03.
What conditions does trial NCT02162511 study?
This clinical trial studies the following conditions: Non Malignant Diseases, Malignant Diseases.
What interventions are being tested in trial NCT02162511?
The interventions under investigation include: CliniMACS CD34+ cell enrichment and T-cell depletion (DEVICE).
Who is sponsoring clinical trial NCT02162511?
This trial is sponsored by Rajni Agarwal, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02162511 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non Malignant Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.